Clinicians managing relapsed/refractory multiple myeloma (RRMM) are increasingly prioritizing individualized sequencing of BCMA-directed therapies, such as CAR T-cell therapy and bispecific antibodies, based on patient fitness, disease kinetics, and treatment access. According to Dr. Binod Dhakal, Dr. Carol Ann Huff, and Dr. Prerna Mewawalla, these decisions require a comprehensive assessment of both clinical and logistical factors to optimize patient outcomes.
How do clinicians choose between CAR T-cell therapy and bispecific antibodies?
Treatment selection in the RRMM space is rarely one-size-fits-all. Dr. Carol Ann Huff notes that the decision-making process is highly individualized, contingent upon the aggressiveness of the disease and the duration of previous remissions. While BCMA-targeted therapies have provided significant clinical benefits, they are not universally required for every patient.
Dr. Prerna Mewawalla adds that the choice between CAR T-cell therapy and bispecific antibodies often hinges on practical constraints. These include:
- Patient Fitness: Assessing the physical resilience of the patient to tolerate specific side effect profiles.
- Disease Kinetics: Evaluating how rapidly the myeloma is progressing.
- Logistics and Access: Considering the patient’s ability to travel to specialized treatment centers.
- Patient Preference: Integrating the patient’s personal goals and lifestyle requirements into the care plan.
Shared decision-making is a component of the treatment process. By aligning clinical goals with patient preferences, doctors can better manage the complexities of long-term RRMM therapy.
Why is sequencing BCMA-directed therapies so complex?
The rise of BCMA-directed therapies has expanded the options for patients. As Dr. Binod Dhakal points out, the landscape is evolving, and clinicians must navigate sequencing decisions among BCMA-directed therapies.
When discussing treatment options, ask your care team about how specific prior therapies might impact your eligibility.
What role does patient assessment play in long-term outcomes?
Comprehensive patient assessment is the cornerstone of managing relapsed/refractory multiple myeloma. According to the panel of experts, clinicians must balance regulatory considerations with the reality of the patient’s situation. While clinical data shows the power of BCMA-targeted approaches, the treatment selection accounts for the patient’s total clinical picture, including prior therapies and overall treatment eligibility.
Frequently Asked Questions
Are all patients with RRMM eligible for CAR T-cell therapy?
No. Eligibility depends on several factors, including disease status, physical fitness, and access to a treatment center, according to Dr. Prerna Mewawalla.
Is BCMA-directed therapy always the next step after relapse?
Not necessarily. Dr. Carol Ann Huff emphasizes that treatment selection depends on the individual patient’s disease aggressiveness and prior response to therapy.
How do logistics affect my treatment plan?
Logistical factors, such as access to treatment centers, are critical components in deciding between CAR T-cell therapy and bispecific antibodies, as highlighted by the expert panel.
Are you or a loved one managing RRMM? Understanding the latest treatment options is a vital step in your care. Subscribe to our newsletter for the latest updates in oncology or visit our patient resource center for more information on clinical decision-making.
